NASDAQ:RCKT - Rocket Pharmaceuticals Stock Price, Forecast & News

Rocket Pharmaceuticals' stock was trading at $15.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RCKT stock has decreased by 12.3% and is now trading at $14.03. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rocket Pharmaceuticals.

Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Rocket Pharmaceuticals.

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) posted its quarterly earnings data on Thursday, March, 5th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.10. View Rocket Pharmaceuticals' earnings history.

6 brokerages have issued 12-month target prices for Rocket Pharmaceuticals' shares. Their forecasts range from $33.00 to $42.00. On average, they expect Rocket Pharmaceuticals' stock price to reach $38.67 in the next year. This suggests a possible upside of 175.6% from the stock's current price. View analysts' price targets for Rocket Pharmaceuticals.

Media headlines about RCKT stock have trended very negative recently, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Rocket Pharmaceuticals earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutRocket Pharmaceuticals.

Some companies that are related to Rocket Pharmaceuticals include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Emergent Biosolutions (EBS), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), HUTCHISON CHINA/S (HCM), PTC Therapeutics (PTCT) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), Amarin (AMRN), Walt Disney (DIS), Energy Transfer LP Unit (ET), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY) and Home Depot (HD).

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Rocket Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (4.45%), FMR LLC (2.53%), Lord Abbett & CO. LLC (2.03%), State Street Corp (1.81%), Goldman Sachs Group Inc. (1.37%) and Geode Capital Management LLC (0.93%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell, Gaurav Shah, Kinnari Patel, Naveen Yalamanchi and Rtw Investments, Lp. View institutional ownership trends for Rocket Pharmaceuticals.

RCKT stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, FMR LLC, State Street Corp, Schonfeld Strategic Advisors LLC, Rafferty Asset Management LLC, Franklin Resources Inc., Franklin Resources Inc., and Credit Suisse AG. View insider buying and selling activity for Rocket Pharmaceuticals.

RCKT stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Farallon Capital Management LLC, Perceptive Advisors LLC, Blair William & Co. IL, Jefferies Group LLC, Monashee Investment Management LLC, Goldman Sachs Group Inc., and California Public Employees Retirement System. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel, and Rtw Investments, Lp. View insider buying and selling activity for Rocket Pharmaceuticals.

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RCKT stock can currently be purchased for approximately $14.03.

Rocket Pharmaceuticals has a market capitalization of $772.63 million. The biotechnology company earns $-77,270,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Rocket Pharmaceuticals employs 33 workers across the globe. View additional information about Rocket Pharmaceuticals.

The official website for Rocket Pharmaceuticals is http://www.rocketpharma.com/.

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]